COVID-19 y la “locura” por la ivermectina
DOI:
https://doi.org/10.35839/repis.4.3.747Descargas
Citas
World Health Organization. Coronavirus disease (COVID-2019) situation reports [Internet]. [citado 1 de abril de 2020]. Disponible en: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 20 de marzo de 2020;105949.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot (Tokyo). 12 de junio de 2020;
Schmith VD, Zhou JJ, Lohmer LRL. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clin Pharmacol Ther. 7 de mayo de 2020;
Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R, Singh BR, et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 30 de mayo de 2020;19(1):23.
Chaccour C, Hammann F, Ramón-García S, Rabinovich NR. Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency. Am J Trop Med Hyg [Internet]. 16 de abril de 2020 [citado 2 de julio de 2020]; Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253113/
